Medical Tourism Vietnam seeks to partner with medical clinics offering treatment with the UroLift® System. UroLift surgery is currently available in Australia, Hong Kong and Singapore. The BPH patients who have undergone the operation have reported excellent results and their quality of life has improved. The UroLift system has been approved by the U.S. Food and Drug Administration to treat low or blocked urine flow in men aged 50 and older who have an enlarged prostate.
Prostate cancer is the second most common cancer in men worldwide and a leading cause of mortality. The prevalence of prostate cancer is relatively low in Vietnam; however, some hospital-based reports have shown an upward trend in recent years. While certain non-modifiable factors such as age, race and genetics are known to be mainly responsible. The present study provides a review of the epidemiology of prostate cancer in Vietnam by systematically searching several electronic databases. The results confirm an increasing trend of prostate cancer over the past decade, with age-standardised rate more than doubled from 2.2 per 100,000 men in 2000 to 4.7 per 100,000 men in 2010. However, no study has been found on modifiable risk factors, with the exception of one in vitro experiment that showed the inhibitory effect of garlic on the growth of prostate cancer cells. The lack of epidemiological information poses a difficulty to develop public health interventions to prevent this emerging malignant disease in Vietnam.
How Does The UroLift® System Work?
The UroLift® System uses a revolutionary approach to treating BPH that lifts and holds the enlarged prostate tissue so it no longer blocks the urethra. It is the only available BPH treatment performed by a urologist that does not require heating, cutting, or removal of the prostate tissue. Patients often return home the same day without a catheter.
The Urolift is a minimally invasive approach that provides rapid relief and recovery of BPH symptoms. It is an early treatment option that can get men off BPH medications and therefore avoiding major surgery. The goal of the UroLift System treatment is to relieve symptoms so you can get back to your life and resume your daily activities.
Is UroLift suitable for all BPH patients?
The Urolift is ideal for patients over 50 year old with a relatively small to moderate sized prostate gland who do not want to take a daily dose of medication and do not want any invasive operations.
How Urolift surgery works and advantages over traditional prostatectomy
The UroLift System treatment is a relatively new procedure for the management of symptomatic benign prostatic hyperplasia (BPH). In contrast to the traditional ablative prostate surgery, UroLift procedure holds the prostate lobes apart by tiny implants. The analogy is like opening up the curtains on a window, to relieve compression of the urethra. This allows urine to flow normally again. There is no cutting, heating or removal of prostate tissue.
Advantages of Urolift surgery over traditional prostatectomy
The UroLift System treatment is a relatively new procedure for the management of symptomatic benign prostatic hyperplasia (BPH). In contrast to the traditional ablative prostate surgery, UroLift procedure holds the prostate lobes apart by tiny implants. The analogy is like opening up the curtains on a window, to relieve compression of the urethra.
Clinical studies have shown the UroLift® System treatment does not cause new, sustained instances of erectile or ejaculatory dysfunction1. The same cannot always be said of other BPH therapies such as TURP, laser, and even medication.
The advantages of UroLift surgery
- Short procedure performed under MAC or LA . Other benefits are:
- Day procedure
- Minimally invasive
- Minimal time off work
- Typically, no catheter or overnight stay required after treatment
- Preservation of sexual function while most other treatments may affect
- Rapid symptom relief, as early as 2 weeks post procedure
Operation time 15 mins or less 60-90 mins
Anaesthesia LA or MAC GA or SA
Tissue concern Compresses Ablates
Erectile Dysfunction 0% 5-9%
Retrograde Ejaculation 0% Mostly
Catheter Occasional All cases
Length of hospital stay less than 24 hours 3 to 5 days
FDA Approved Enlarged Prostate Urine Flow Device
The new device, which helps prevent the prostate from pressing on the urethra, was evaluated in clinical studies involving 274 men between the ages of 49 and 86. Participants given the device reported fewer symptoms of enlarged prostate and a better quality of life, the FDA said.
The most common adverse reactions included pain or burning during urination, blood in the urine, and incomplete emptying of the bladder.
The UroLift system is produced by NeoTract Inc., based in Pleasanton, Calif.